Back to top
more

Novartis (NVS)

(Real Time Quote from BATS)

$118.62 USD

118.62
90,930

+0.12 (0.10%)

Updated Sep 4, 2024 10:12 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (61 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Roche's (RHHBY) 1H20 Sales Hit by the Coronavirus Pandemic

by Zacks Equity Research

Roche's (RHHBY) performance in first-half 2020 was unimpressive as it bears the brunt of the COVID-19 outbreak.

Biogen to Pit Spinraza Against Novartis' Zolgensma in Phase IV

by Zacks Equity Research

Biogen (BIIB) intends to start a phase IV study for the assessment of Spinraza's safety in infants and children with SMA who showed a suboptimal clinical response to Novartis' Zolgensma.

AbbVie's Rinvoq Meets Late-Stage Eczema Study Endpoints

by Zacks Equity Research

AbbVie's (ABBV) JAK inhibitor, Rinvoq monotherapy achieves improvement in skin clearance and reduction in itch in significantly higher proportion of atopic dermatitis patients in a phase III study.

Company News for Jul 22, 2020

by Zacks Equity Research

Companies In The News Are: PM, SYF, NVS, PACR.

Novartis' (NVS) Q2 Earnings Surpass Estimates, Sales Miss

by Zacks Equity Research

Novartis' (NVS) second-quarter 2020 sales take a hit due to the coronavirus pandemic.

Lilly's Plaque Psoriasis Candidate Meets Phase III Study Goals

by Zacks Equity Research

Lilly's (LLY) autoimmune disorder candidate, mirikizumab, superior to Cosentyx in a phase III study for patients with moderate-to-severe plaque psoriasis.

Bristol-Myers' (BMY) CAR T Cell Therapy Gets EMA Validation

by Zacks Equity Research

Bristol-Myers' (BMY) MAA for its experimental candidate, liso-cel, gets validated by EMA.

Merck's NDA for Heart Failure Candidate Gets Priority Review

by Zacks Equity Research

FDA decision on Merck (MRK) and its Germany-based partner Bayer's vericiguat as a treatment to reduce heart failure is expected in January 2021.

Daniel Laboe headshot

What To Expect From The Crazy Earnings Season Ahead

by Daniel Laboe

Are Netflix's disappointing results a foreshadowing of what is to come from the most parabolic tech stocks this earnings season?

Ceylad Gets FDA Nod to Begin Phase I Study on CAR T Candidate

by Zacks Equity Research

Celyad (CYAD) gets the FDA's permission to begin a phase I study on its lead CAR T candidate, CYAD-211, for the treatment of relapsed/refractory multiple myeloma.

Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

by Zacks Equity Research

Sector ETF report for PPH

Biogen/Eisai's New BAN2401 Study for Alzheimer's Begins

by Zacks Equity Research

A new phase III study has been initiated to evaluate Biogen (BIIB) and Eisai's BAN2401 to treat preclinical Alzheimer's disease.

Biogen Files BLA for Alzheimer's Drug Aducanumab, Stock Up

by Zacks Equity Research

If Biogen's (BIIB) aducanumab is approved by the FDA, it will become the first medicine to be approved to reduce the clinical decline associated with Alzheimer's disease.

Endo (ENDP) Obtains FDA Approval for Cellulite Treatment

by Zacks Equity Research

Endo (ENDP) gains FDA approval for Qwo (collagenase clostridium histolyticum-aaes) for the treatment of cellulite.

Novartis Gets EC Approval for Enerzair Breezhaler for Asthma

by Zacks Equity Research

Novartis (NVS) gets EC approval for Enerzair Breezhaler as a maintenance treatment for asthma.

The Zacks Analyst Blog Highlights: Novartis, Equinix, Newmont, Enterprise Products Partners and Franco-Nevada

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Novartis, Equinix, Newmont, Enterprise Products Partners and Franco-Nevada

Sheraz Mian headshot

Top Analyst Reports for Novartis, Equinix & Newmont

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Novartis (NVS), Equinix (EQIX) and Newmont (NEM).

Amgen Gets Favorable Appeals Court Ruling for Enbrel Patent

by Zacks Equity Research

An appeals court ruled in Amgen's (AMGN) favor in a case challenging the validity of two patents on its top-selling medicine, Enbrel.

Novartis Gets Positive CHMP View for Cosentyx Label Expansion

by Zacks Equity Research

Novartis' (NVS) Cosentyx gets positive CHMP opinion for moderate-to-severe plaque psoriasis in children and adolescents aged 6-18 years.

Bristol Myers & Acceleron Obtain EC Approval for Reblozyl

by Zacks Equity Research

Bristol Myers (BMY) and partner Acceleron win EC approval of Reblozyl (luspatercept) for two indications.

AbbVie's Eye Disorder Candidate Gets Complete Response Letter

by Zacks Equity Research

AbbVie (ABBV) unit Allergan's abicipar pegol demonstrates unfavorable benefit-risk ratio in patients with nAMD, an eye disorder. The FDA issues a complete response letter.

Global Blood to Seek Approval of Oxbryta in Europe for SCD

by Zacks Equity Research

Global Blood (GBT) plans to seek approval for Oxbryta tablets to treat hemolytic anemia in SCD patients aged 12 years and older in Europe.

Novartis Discontinues HCQ Study Due to Enrollment Challenges

by Zacks Equity Research

Novartis (NVS) abandons its HCQ study in COVID-19 patients due to enrollment challenges.

Alpine Skyrockets on License Deal With AbbVie for ALPN-101

by Zacks Equity Research

Alpine (ALPN) signs an agreement with AbbVie granting exclusive worldwide option and license to its pipeline candidate, ALPN-101. The deal significantly boosts Alpine's funds.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Approvals to MRK, LLY, NVS and GSK's Drugs

by Kinjel Shah

FDA approves expanded labels of Merck (MRK), Novartis (NVS) and Glaxo (GSK) drugs and Lilly's (LLY) new insulin.